Edwards Lifesciences (EW) Liabilities and Shareholders Equity (2009 - 2026)

Edwards Lifesciences has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $13.9 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 2.81% year-over-year to $13.9 billion in Q2 2026; TTM through Jun 2026 was $54.2 billion, a 3.08% increase from a year earlier, with the FY2025 full-year figure at $13.7 billion, up 4.92% from the prior year.
• Liabilities and Shareholders Equity was $13.9 billion for Q2 2026 at Edwards Lifesciences, up from $13.3 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $13.9 billion in Q2 2026, with the low at $8.3 billion in Q4 2022.
• Average Liabilities and Shareholders Equity over 5 years is $10.9 billion, with a median of $9.9 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity decreased 2.47% in 2022, then jumped 39.43% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $8.3 billion in 2022, then advanced by 12.91% to $9.4 billion in 2023, then surged by 39.43% to $13.1 billion in 2024, then increased by 4.92% to $13.7 billion in 2025, then gained by 1.24% to $13.9 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $13.9 billion (Q2 2026), $13.3 billion (Q1 2026), and $13.7 billion (Q4 2025), per Business Quant data.